Harmony Biosciences Holdings, Inc. (HRMY) P/E ratio
Harmony Biosciences Holdings, Inc. (HRMY) trades at 10.9× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 13.8×. That is 0.7% higher than the 13.7× of fiscal 2024. Figures as of 18 Nov 2026, 12:28 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/E ratio today
- 10.9×
- P/E ratio, fiscal 2025
- 13.8×
- Change on fiscal 2024
- +0.7%
- Highest on record
- 73.5×fiscal 2021
- Lowest on record
- 13.7×fiscal 2024
- Fiscal years on record
- 52021–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Harmony Biosciences Holdings, Inc. P/E ratio, in more detail
Today's figure is 20.8% below the fiscal 2025 year-end.
Across the 5 fiscal year-ends on record (2021–2025), the highest was 73.5× in fiscal 2021 and the lowest 13.7× in fiscal 2024. Today's P/E ratio is at or below every one of the 5 fiscal year-ends on record; their median is 15.2×.
P/E ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Harmony Biosciences Holdings, Inc. P/E ratio, year by year
| Fiscal year | P/E ratio | Change | Year ended | Share price at year-end | Diluted EPS |
|---|---|---|---|---|---|
| Today | 10.9× | — | $33.01 | — | |
| 2025 | 13.8× | 0.7% up | $37.42 | $2.71 | |
| 2024 | 13.7× | 9.6% down | $34.41 | $2.51 | |
| 2023 | 15.2× | 18.3% down | $32.30 | $2.13 | |
| 2022 | 18.6× | 74.8% down | $55.10 | $2.97 | |
| 2021 | 73.5× | — | $42.64 | $0.58 | |
| 2020 | — | — | $36.15 | -$2.48 | |
| 2019 | — | — | — | -$24.07 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
How to read it
It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.
Harmony Biosciences Holdings, Inc., figure by figure
- Harmony Biosciences Holdings, Inc. market cap
- Harmony Biosciences Holdings, Inc. revenue
- Harmony Biosciences Holdings, Inc. earnings
- Harmony Biosciences Holdings, Inc. earnings per share (EPS)
- Harmony Biosciences Holdings, Inc. P/S ratio
- Harmony Biosciences Holdings, Inc. P/B ratio
- Harmony Biosciences Holdings, Inc. free cash flow
- Harmony Biosciences Holdings, Inc. operating margin
- Harmony Biosciences Holdings, Inc. dividend
- Harmony Biosciences Holdings, Inc. shares outstanding
- Harmony Biosciences Holdings, Inc. total debt
- Harmony Biosciences Holdings, Inc. cash on hand
- Harmony Biosciences Holdings, Inc. total assets
- Harmony Biosciences Holdings, Inc. return on equity (ROE)
- Harmony Biosciences Holdings, Inc. return on invested capital (ROIC)
Harmony Biosciences Holdings, Inc. (HRMY) overview: price, valuation and scorecard
Harmony Biosciences Holdings, Inc. P/E ratio: questions and answers
What is Harmony Biosciences Holdings, Inc.'s P/E ratio?
Harmony Biosciences Holdings, Inc. (HRMY) trades at 10.9× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 13.8×. That is 0.7% higher than the 13.7× of fiscal 2024.
Is Harmony Biosciences Holdings, Inc.'s P/E ratio high or low compared with its own history?
Today's P/E ratio is at or below every one of the 5 fiscal year-ends on record; their median is 15.2×.
What are the highest and lowest P/E ratio figures on record for Harmony Biosciences Holdings, Inc.?
Across the 5 fiscal year-ends on record (2021–2025), the highest was 73.5× in fiscal 2021 and the lowest 13.7× in fiscal 2024.
How is Harmony Biosciences Holdings, Inc.'s P/E ratio calculated?
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E. For Harmony Biosciences Holdings, Inc. it is on record here for 5 fiscal years, 2021 to 2025.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/E ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Harmony Biosciences Holdings, Inc. (HRMY) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/HRMY/pe-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.